Very Low Viral Load (VLVL) Relapse Following Treatment of Naïve Patients with Chronic Hepatitis C
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Sustained virologic response (SVR) to treatment of naïve patients with chronic hepatitis C (HCV) with pegylated interferon and ribavirin is 50–60%. Patients who relapse have a poor response to re-treatment. We report a group of relapse patients with SVR to low-dose re-treatment after 6 months.
Characterization of HCV relapse patients with very low viral load (VLVL) (HCV RNA <5,000 IU/ml) 6 months after stopping full-dose initial treatment.
We identified 120 consecutive naïve patients over 4 years treated with pegylated interferon alpha-2a and ribavirin with full-dose therapy for 24 weeks (non-genotype 1) or 48 weeks (genotype 1) with baseline liver biopsy and at least 6 months of follow-up after treatment. HCV RNA by PCR and hepatic blood tests were obtained monthly during treatment and at least 1, 3, and 6 months post treatment.
Of the initially treated patients, 54.2% had SVR, 25% non-response and 20.8% relapsed. Four of 25 who relapsed (16%) and one similar patient referred to our program had HCV RNA <5,000 IU/ml 6 months after stopping treatment (VLVL relapse). Significant differences (P < 0.05) compared with the 21 other relapse patients included all five patients who were genotype 1; 4/5 had cirrhosis, baseline HCV RNA was lower, and all had SVR to less intensive re-treatment for 6 months.
VLVL relapse patients should be sought, because SVR to re-treatment is common despite genotype 1 cirrhosis.
- Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature. 2005;436:946–952. CrossRef
- Farci P, Alter HJ, Wong DC, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA. 1994;91:7792–7796. CrossRef
- Thimme R, Bukh J, Spangenberg HC, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA. 2002;99:15661–15668. CrossRef
- Osburn WO, Fisher BE, Dowd KA, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology. 2009;138:315–324. CrossRef
- Sallie R. Replicative homeostasis: a fundamental mechanism mediating selective viral replication and escape mutation. Virol J. 2005;2:10–24. CrossRef
- Dubuisson J. Hepatitis C virus proteins. World J Gastroenterol. 2007;13:2406–2415.
- Dustin LB, Rice CM. Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol. 2007;25:71–99. CrossRef
- Miyanari Y, Atsuzawa K, Usuda N, et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol. 2007;9:1089–1097. CrossRef
- Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest. 2009;119:1745–1754. CrossRef
- Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA. 2008;105:7034–7039. CrossRef
- Hofer H, Watkins-Riedel T, Janata O, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology. 2003;37:60–64. CrossRef
- Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous, treatment-induced viral clearance. Gastronenterology. 2003;125:80–88. CrossRef
- Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34:395–403. CrossRef
- Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965. CrossRef
- Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982. CrossRef
- Bruno S, Cammà C, Di Marco V, et al. Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol. 2004;41:474–481. CrossRef
- Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355.
- Davis GL, Esteban-Mur R, Rustgi V, et al. The international hepatitis interventional therapy group interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med. 1998;339:1493–1499. CrossRef
- Berg C, Goncales L, Bernstein DE, et al. Re-treatment of chronic hepatitis C patients after relapse: efficacy of perinterferon alpha-2a (40 kDa) and ribavirin. J Viral Hepat. 2006;13:435–440. CrossRef
- Hoefs J, Aulakh VS. Treatment of chronic HCV infection in special populations. Int J Med Sci. 2006;3:69–74.
- Sherman M, Yoshida EM, Deschenes M, et al. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut. 2006;55:1631–1638. CrossRef
- Hoefs JC, Wang F, Kanel G. Functional measurement of the non-fibrotic hepatic mass in cirrhotic patients. Am J Gastroenterol. 1997;92:2054–2058.
- Hoefs JC, Chen PT, Lizotte P. Non-invasive evaluation of liver disease severity. Clin Liver Dis Dec. 2006;10:535–562. CrossRef
- Arase Y, Suzuki F, Akuta N, et al. Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load. Intern Med. 2009;48:253–258. CrossRef
- McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827. CrossRef
- Manns M, Muir A, Adda N, et al. Telaprevir in hepatitis C genotype-1-infected patients with prior non-response, viral breakthrough or relapse to peginterferon-alfa-2a/b and ribavirin therapy: SVR results of the PROVE3 study [abstract]. Presented at the 44th annual meeting of the European association for the study of the liver, Copenhagen, Denmark; April 22–26, 2009; abstract #1044.
- Kwo, P, Lawitz EJ, McCone J, et al. HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus pegintron (peginterferon alfa-2b)/ribavirin in treatment-naïve subjects with genotype 1 chronic hepatitis C [abstract]. Presented at the 44th annual meeting of the European association for the study of the liver, Copenhagen, Denmark; April 22–26, 2009; abstract #4.
- Hoefs JC, Chang K, Wang F, Kanel G, Morgan T, Braunstein P. Perfused kupffer cell mass: correlation with histology and severity of CLD. Dig Dis Sci. 1995;40:552–560. CrossRef
- Hoefs JC, Wang F, Kanel G, Braunstein P. The liver-spleen scan as a quantitative liver function test: correlation with liver severity at peritoneoscopy. Hepatology. 1995;22:1113–1121. CrossRef
- Everson GT, Shiffman ML, Hoefs JC, et al. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the HALT-C trial. Hepatology. 2011. doi:10.1002/hep.24752.
- Everson GT, Hoefs JC, Seeff LB, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology. 2006;44:1675–1684. CrossRef
- Everson GT, Shiffman ML, Morgan TR, et al. The spectrum of hepatic functional impairment in patients with fibrosis and compensated cirrhosis due to chronic hepatitis C: results from the HALT-C trial. Aliment Pharmacol Ther. 2008;27:798–809. CrossRef
- Everson GT, Shiffman ML, Hoefs JC, et al. Quantitative tests of liver function measure hepatic improvement after sustained virologic response: results from the HALT-C trial. Aliment Pharmacol Ther. 2009;29:589–601. CrossRef
- McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061–1069. CrossRef
- Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology. 2007;132:103–112. CrossRef
- Krawitt EL, Gordon SR, Grace ND, et al. A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol. 2006;101:1268–1273. CrossRef
- Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006;43:954–960. CrossRef
- Arase Y, Suzuki F, Sezaki H, et al. Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C. Intern Med. 2008;47:1301–1307. CrossRef
- Schalm SW, Weiland O, Hansen BE, et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Gastroenterology. 1999;117:408–413. CrossRef
- Bassett SE, Guerra B, Brasky K, et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology. 2001;33:1479–1487. CrossRef
- Major ME, Mihalik K, Puig M, et al. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol. 2002;76:6586–6595. CrossRef
- Bukh J, Thimme R, Meunier JC, et al. Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J Virol. 2008;82:8183–8195. CrossRef
- Dahari H, Major M, Zhang X, et al. Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. Gastroenterology. 2005;128:1056–1066. CrossRef
- Major ME. Prophylactic and therapeutic vaccination against hepatitis C virus (HCV): developments and future perspectives. Viruses. 2009;1:144–165. CrossRef
- Major ME, Dahari H, Mihalik K, et al. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology. 2004;39:1709–1720. CrossRef
- Very Low Viral Load (VLVL) Relapse Following Treatment of Naïve Patients with Chronic Hepatitis C
Digestive Diseases and Sciences
Volume 57, Issue 1 , pp 243-249
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Very low viral load hepatitis C genotype 1
- Sustained virologic response
- Pegylated interferon alpha-2a
- Industry Sectors
- Author Affiliations
- 1. Division of Gastroenterology and Hepatology, H. H. Chao Comprehensive Digestive Disease Center, UCI Medical Center, 101 The City Drive South, Building 53, Room 113, Orange, CA, 92868, USA
- 2. Mercy Hospital and Medical Center, 2525 South Michigan Ave, Chicago, IL, 60616, USA